Position in EXEL
as of Jun 30, 2026
· filed Jul 27, 2026
Position Value
$226,182
+$1,439 QoQ
Shares Held
4,157
-20.7% QoQ
Ownership
0.002%
of shares outstanding
% of Portfolio
0.03%
of 13F equity value
Holder Rank
#566
of 751 holders
Holding Since
Jun 2024
9 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in EXEL Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Claret Asset Management Corp holds $1,581,307 across 7 Biotechnology names. EXEL ranks #4 (14.3% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | HALO |
Halozyme Therapeutics, Inc.
|
2,923 | $228,783 | |
| 2 | JAZZ |
Jazz Pharmaceuticals plc
|
948 | $228,439 | |
| 3 | CORT |
Corcept Therapeutics Inc
|
2,606 | $226,591 | |
| 4 | EXEL |
Exelixis, Inc.
This page
|
4,157 | $226,182 | |
| 5 | TECH |
BIO-TECHNE Corp
|
3,182 | $224,808 | |
| 6 | BMRN |
Biomarin Pharmaceutical Inc
|
3,913 | $223,901 | |
| 7 | REGN |
Regeneron Pharmaceuticals, Inc.
|
357 | $222,603 |
All Filings in EXEL
Export CSV
9 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $226,182 | 4,157 | Shares | Sole | 2026-07-27 | |
| 2026-03-31 | $224,743 | 5,240 | Shares | Sole | 2026-05-11 | |
| 2025-12-31 | $229,625 | 5,239 | Shares | Sole | 2026-02-11 | |
| 2025-09-30 | $216,866 | 5,251 | Shares | Sole | 2025-11-13 | |
| 2025-06-30 | $234,770 | 5,326 | Shares | Sole | 2025-08-13 | |
| 2025-03-31 | $332,944 | 9,018 | Principal | Sole | 2025-05-13 | |
| 2024-12-31 | $300,099 | 9,012 | Shares | Sole | 2025-02-13 | |
| 2024-09-30 | $232,226 | 8,949 | Shares | Sole | 2024-11-14 | |
| 2024-06-30 | $200,027 | 8,902 | Shares | Sole | 2024-08-14 | |
| No filing history on record for this holder in this stock. | ||||||